Literature DB >> 17949066

Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells.

Alina Nemirovski1, Yonit Kasherman, Yael Tzaraf, Dan Gibson.   

Abstract

Pt(IV) complexes must be reduced to kill cancer cells. While reduction rates correlate with reduction potentials, we wanted to check if the rates of reduction depend on the cell line used. The reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by extracts of three cell lines was measured, and the rates follow the order A2780cisR > A2780 > HT-29. The reduction is not carried out by the low molecular weight (MW) antioxidants but primarily by cellular components with MW > 3000.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949066     DOI: 10.1021/jm070740j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

3.  Elusive Intermediates in the Breakdown Reactivity Patterns of Prodrug Platinum(IV) Complexes.

Authors:  Davide Corinti; Maria Elisa Crestoni; Simonetta Fornarini; Fortuna Ponte; Nino Russo; Emilia Sicilia; Elisabetta Gabano; Domenico Osella
Journal:  J Am Soc Mass Spectrom       Date:  2019-04-12       Impact factor: 3.109

4.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

Review 5.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

6.  Encapsulation of Pt(IV) Prodrugs within a Pt(II) Cage for Drug Delivery.

Authors:  Yao-Rong Zheng; Kogularamanan Suntharalingam; Timothy C Johnstone; Stephen J Lippard
Journal:  Chem Sci       Date:  2015-02-01       Impact factor: 9.825

7.  Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.

Authors:  Dina Tolan; Valentina Gandin; Liam Morrison; Ahmed El-Nahas; Cristina Marzano; Diego Montagner; Andrea Erxleben
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

8.  Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.

Authors:  Vojtech Novohradsky; Ilaria Zanellato; Cristina Marzano; Jitka Pracharova; Jana Kasparkova; Dan Gibson; Valentina Gandin; Domenico Osella; Viktor Brabec
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

9.  Bioorthogonal Catalytic Activation of Platinum and Ruthenium Anticancer Complexes by FAD and Flavoproteins.

Authors:  Silvia Alonso-de Castro; Aitziber L Cortajarena; Fernando López-Gallego; Luca Salassa
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-15       Impact factor: 15.336

10.  The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs - an HPLC-ICP-MS study.

Authors:  Sarah Theiner; Márkó Grabarics; Luis Galvez; Hristo P Varbanov; Nadine S Sommerfeld; Mathea S Galanski; Bernhard K Keppler; Gunda Koellensperger
Journal:  Dalton Trans       Date:  2018-04-17       Impact factor: 4.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.